香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 承董事會命 江蘇荃信生物醫藥股份有限公司 董事會主席及執行董事 裘霽宛先生 長效雙抗QX027N獲得兩項臨床試驗默示許可 本 公 告 乃 由 江 蘇 荃 信 生 物 醫 藥 股 份 有 限 公 司（「本公司」）自 願 刊 發，以 向 股 東 及 潛 在投資者提供本公司最新的業務發展狀況。 本 公 司 董 事 會（「 董事會 」）欣 然 宣 佈， 本 公 司 自 主 研 發 的 長 效 雙 抗QX027N注 射 液 獲 得 國 家 藥 品 監 督 管 理 局 藥 品 審 評 中 心 的 臨 床 試 驗 默 示 許 可（ 受 理 號： CXSL2500757，CXSL2500758），擬 用 於 治 療 哮 喘 及 特 應 性 皮 炎。該 候 選 藥 物 的 臨 床 許可標誌著本公司在自免及過敏疾病領域的創新雙抗矩 陣 正式邁入臨床階段。 QX02 ...

Group 1: Solar and Energy Stocks - Solar stocks showed recovery with New Special Energy (01799) up 4.99%, Flat Glass (06865) up 3.25%, Xinyi Solar (00968) up 3.75%, and GCL-Poly Energy (03800) up 2.27%. The China Photovoltaic Industry Association stated that rumors about a polysilicon storage platform were false, aiming to malign the industry [1][2] - Energy storage concept stocks rose against the trend, with Longpan Technology (02465) up 17.09%, Ruipu Lanjun (00666) up 15.2%, and Zhongxin Innovation (03931) up 9.22%. Lithium hexafluorophosphate prices have surged, with some market quotes reaching 150,000 yuan/ton, doubling since mid-October [1] Group 2: Oil and Gas Stocks - Oil stocks collectively declined, with CNOOC (00883) down 3.14%, CNOOC Services (02883) down 2.98%, PetroChina (00857) down 2.09%, and Sinopec (00386) down 1.79%. OPEC's monthly report indicated a slight oversupply in the oil market by 2026, contrasting previous predictions of sustained demand [2] Group 3: Steel and Mining Stocks - Steel stocks saw a midday surge, with Maanshan Iron & Steel (00323) up 7.09%, Ansteel (00347) up 2.26%, and Chongqing Iron & Steel (01053) up 2.13%. The Simandou project in Guinea, which has the potential to become the fifth-largest mine globally, has commenced production [2] Group 4: Airline and Transportation Stocks - Southern Airlines (01055) rose over 3.9% after reporting a 2.2% year-on-year increase in revenue for the first three quarters of 2025 [2] Group 5: Biotechnology and Pharmaceuticals - Gilead Sciences (01672) increased over 5.7% as it announced the clinical development of new drugs ASC36 and ASC35 [3] - Zai Lab (02509) rose over 8.4% after announcing plans for continued related transactions for the commercialization of QX001S from 2026 to 2028 [4] Group 6: Gold Stocks - Gold stocks collectively rose, with China Gold International (02099) up 5.99%, Jihai Resources (02489) up 7.3%, and Lingbao Gold (03330) up 4.47%. Gold prices have surpassed $4,100 and are testing the $4,200 resistance level [4] Group 7: US Market Movements - Major tech stocks in the US fell, with Meta Platforms (META.US) down over 2.8%, Tesla (TSLA.US) down over 2%, and Amazon (AMZN.US) down over 1.9% [5] - Eli Lilly (LLY.US) rose 2.95%, reaching a historical high, after announcing a deal to lower GLP-1 drug prices to $245 per month, potentially opening a new market of 30 million people [5] - The US airline service sector saw gains, with United Airlines (UAL.US) up 5.29% and American Airlines (AAL.US) up 3.62%, as the government is expected to reopen soon [5] Group 8: Nuclear Energy Stocks - US nuclear energy stocks rose, with Oklo (OKLO.US) up 6.67% as the government plans to finance new nuclear power plants to meet the energy demands of AI development [6] Group 9: Company-Specific Developments - On Holding (ONON.US) surged over 17.9% after reporting Q3 net sales of 794.4 million Swiss francs, exceeding market expectations [7] - AMD (AMD.US) rose 9% as it projected a 35% annual growth rate in revenue over the next three to five years, driven by AI chip demand [7]

Group 1 - The stock of Zai Lab Limited (荃信生物-B) increased by over 10%, reaching HKD 20.92 with a trading volume of HKD 10.62 million [1] - The board of directors has proposed a new annual cap for continuing connected transactions for the fiscal years 2026 to 2028, based on the business needs following the commercialization of QX001S [1] - The profit-sharing cap is expected to rise significantly from RMB 55 million in 2026 to RMB 290 million in 2028 [1] Group 2 - Zai Lab has entered into a global exclusive collaboration and licensing agreement with Roche for its self-developed long-acting dual antibody QX031N [2] - Under the agreement, Roche will receive exclusive global rights for research, development, registration, production, and commercialization of QX031N, with Zai Lab receiving an upfront payment of USD 75 million and up to USD 995 million in milestone payments [2] - Zai Lab is recognized as a leader in the domestic innovative autoimmune drug sector, with a mature pipeline that is moving towards realization, enhancing its financial capabilities [2]

Core Viewpoint - The stock of Zai Lab Limited (荃信生物-B) has increased by over 10%, reaching HKD 20.92, following announcements regarding its business strategies and partnerships in the biopharmaceutical sector [1][2]. Group 1: Business Developments - The board of Zai Lab has proposed a new annual cap for related transactions under the QX001S framework agreement for the fiscal years 2026 to 2028, with profit-sharing limits expected to rise significantly from RMB 55 million in 2026 to RMB 290 million in 2028 [1]. - Zai Lab has entered into a global exclusive collaboration and licensing agreement with Roche for its self-developed long-acting dual antibody QX031N, which includes an upfront payment of USD 75 million and potential milestone payments up to USD 995 million, along with tiered royalties on future product sales [2]. Group 2: Market Position and Outlook - Zai Lab is recognized as a leader in the domestic self-immune innovative drug sector, with a strong foundation in this field [2]. - The company's mature pipeline is approaching a monetization phase, and its innovative pipeline is seeing successful international licensing agreements, which further supports its stable operations [2].

江蘇荃信生物醫藥股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2509） 持續關連交易： 重 續QX001S框架協議年度上限 及 建議修訂本公司之公司章程 茲提述本公司刊發的日期為2024年3月12日 的 招 股 章 程（內 容 有 關 本 公 司 與 中 美 華東訂立的QX001S框 架 協 議）及 本 公 司 日 期 為2024年9月12日 的 公 告。除 另 有 界 定者外，本公告所用詞彙與招股章程及該公告所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qyuns Therapeutics Co., Ltd. 董事會已考慮賽樂信® （QX001S）商 業 化 後 的 業 務 需 要，並 建 議 根 據QX001S框 架 協議的條款為2026年 至2028年三個財政年度的持續關連交易重續新年度上限。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qyuns Therapeutics Co., Ltd. 江蘇荃信生物醫藥股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2509） 持續關連交易： 重 續QX001S框架協議年度上限 及 建議修訂本公司之公司章程 茲提述本公司刊發的日期為2024年3月12日 的 招 股 章 程（內 容 有 關 本 公 司 與 中 美 華東訂立的QX001S框 架 協 議）及 本 公 司 日 期 為2024年9月12日 的 公 告。除 另 有 界 定者外，本公告所用詞彙與招股章程及該公告所界定者具有相同涵義。 – 1 – 本公司將召開臨時股東大會供獨立股東考慮及酌情批准 重 續 新 年 度 上 限。於 本 公告日期，中美華東持有本公司已發行股本（不包括本公司持作庫存股份的股份） 的15.85%。因此 ...

智通财经APP讯，荃信生物-B(02509)公布，2025年11月11日耗资约99.88万港元回购5.22万股股份。 ...

格隆汇11月11日丨荃信生物-B(02509.HK)公告，11月11日耗资99.9万港元回购5.22万股。 ...

公司名稱： 江蘇荃信生物醫藥股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年11月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包 ...

Summary of Key Points Core Viewpoint - Multiple companies conducted share buybacks on November 10, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 9.753 million shares for a total of 43.2831 million yuan, representing 0.919% of its total share capital [2]. - China Merchants Industry Holdings (01919) repurchased 3 million shares for 42.5626 million yuan, accounting for 0.562% of its total share capital [2]. - Sinopec Limited (00386) repurchased 4.072 million shares for 17.7963 million yuan, which is 0.110% of its total share capital [2]. Group 2: Other Notable Buybacks - Yimai Sunshine (N23020) repurchased 929,000 shares for 14.9596 million yuan, representing 0.712% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.31 million shares for 7.4321 million yuan, which is 4.518% of its total share capital [2]. - Gushengtang (02273) repurchased 250,000 shares for 7.4123 million yuan, accounting for 3.541% of its total share capital [2].